Breaking News
November 14, 2018 - Study defines biomarker in response to treatment of castration-resistant prostate cancer
November 14, 2018 - Study identifies potential therapeutic strategy for patients with clear cell renal cancer
November 14, 2018 - Bausch Health Announces U.S. Launch of Bryhali (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis In Adults
November 14, 2018 - Alpha Fetoprotein (AFP) Tumor Marker Test: MedlinePlus Lab Test Information
November 14, 2018 - Researchers evaluate controversial treatment for Parkinson’s disease psychosis
November 14, 2018 - AI could help veterinarians code their notes
November 14, 2018 - Pre-schoolers with autism thrive in mainstream classroom settings
November 14, 2018 - Complementary and alternative medicine is widely used by general population in England
November 14, 2018 - Study reveals link between tobacco availability and smoking during pregnancy
November 14, 2018 - Purdue researchers develop translucent base for silicon patches to deliver exact doses of biomolecules
November 14, 2018 - New technology based on moths and magnets could help treat genetic diseases
November 14, 2018 - Concussion-Related Biomarkers Vary Based on Sex, Race
November 14, 2018 - One more year of high school may shape waistlines later in life
November 14, 2018 - Dissecting high drug costs – Scope
November 14, 2018 - Study shows novel strategy to reduce breast cancer bone metastasis
November 14, 2018 - Empowering the NHS through Industry Partnerships
November 14, 2018 - One size does not fit all in obesity treatment, study finds
November 14, 2018 - Seeking ways to prevent ‘secondary cataracts’
November 14, 2018 - Change Within the Eye May Be Early Warning for Macular Degeneration
November 14, 2018 - Study of 500,000 people clarifies the risks of obesity
November 14, 2018 - Ultrasound releases drug to alter activity in targeted brain areas in rats | News Center
November 14, 2018 - Umass Amherst researchers battle against youth suicide in rural Alaska Native communities
November 14, 2018 - Cancer stem cells depend on amino acid metabolism, and it’s proving to be their Achilles’ heel
November 14, 2018 - Epigenetic link found between prenatal exposure to maternal smoking and offspring’s cardio-metabolic health
November 14, 2018 - Meditation, music may change biomarkers of cellular aging and Alzheimer’s disease in older adults
November 14, 2018 - Multidisciplinaryresearch teams selected to study age-related brain disorders
November 14, 2018 - The Current issue of “The view from here” is concerned with Informatics
November 14, 2018 - Researchers identify tool to help transgender women have a more authentic voice
November 14, 2018 - Four faculty members appointed to endowed professorships | News Center
November 13, 2018 - Research finds strongest evidence yet that obesity causes depression
November 13, 2018 - Researchers compare stools of breastfed and formula-fed infants
November 13, 2018 - Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in The New England Journal of Medicine
November 13, 2018 - Gene changes driving myopia reveal new focus for drug development
November 13, 2018 - $6 million grant to support study of preeclampsia, atherosclerosis links | News Center
November 13, 2018 - Beneficial gut microbes metabolize high-fiber diet to improve heart health in mouse model
November 13, 2018 - Excessive use of social media through visual postings linked to increase in narcissistic traits
November 13, 2018 - Study finds why obesity both fuels cancer growth and helps immunotherapy to kill tumors
November 13, 2018 - Women prefer and invest more in daughters, while men favor sons
November 13, 2018 - With hospitalization losing favor, judges order outpatient mental health treatment
November 13, 2018 - Transgenic rat model may provide new insights into cerebral amyloid angiopathy
November 13, 2018 - Study identifies factors tied to greater risk of advanced liver disease in cystic fibrosis patients
November 13, 2018 - Risk of blindness among premature babies with low levels of blood platelets
November 13, 2018 - A new strategy for combatting antibiotic-resistant infections
November 13, 2018 - Study aims to find which outreach method is more effective at improving cancer screening rates
November 13, 2018 - Insufficient sleep duration linked with unhealthy lifestyle profile among children
November 13, 2018 - IIASA researchers introduce new, simple measure for human wellbeing
November 13, 2018 - Magnetic nanosprings used as targeted drug delivery agents for anticancer therapy
November 13, 2018 - Scientists examine FCMs containing silver nanoparticles
November 13, 2018 - Failed DNA repair triggers chromosomal chaos
November 13, 2018 - Study shows new emerging role of osteopontin in HCV-related hepatocellular carcinoma
November 13, 2018 - Food insecurity during pregnancy linked to severity of neonatal abstinence syndrome
November 13, 2018 - Majority of Americans are concerned about health threat posed by antibiotic resistance
November 13, 2018 - Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
November 13, 2018 - Study finds women with pregnancy-related nausea, vomiting use marijuana more
November 13, 2018 - Lethal heart rhythm more likely to be found in patients with common heart failure
November 13, 2018 - Study provides new clues to origin and development of multiple sclerosis
November 13, 2018 - Climate change could pose threat to male fertility
November 13, 2018 - Researchers discover how mitochondria deploy a powerful punch against disease-causing bacteria
November 13, 2018 - AHA: Traumatic Childhood Could Increase Heart Disease Risk in Adulthood
November 13, 2018 - Feeling the Burn? | NIH News in Health
November 13, 2018 - Women’s birth canals in Kenya, Korea, Kansas not the same: study
November 13, 2018 - Fecal microbiota transplantation effective against ICI-associated colitis
November 13, 2018 - New physical activity guidelines released that urge people to “move more”
November 13, 2018 - Angiotensin receptor blockers improve sodium excretion in blacks
November 13, 2018 - New project seeks to address alarming injury rate in youth footballers
November 13, 2018 - Fish oil or omega 3 fatty acid supplements can prevent heart attacks finds study
November 13, 2018 - The Human Heart-in-a-Jar That Could One Day Replace Animal Testing
November 13, 2018 - Treat patients’ partners without a doctor visit
November 13, 2018 - Belgian beer landscape mapped using scientific insights
November 13, 2018 - ‘Master key’ gene has links to both ASD and schizophrenia
November 13, 2018 - Gladstone scientists gain new insights into the aging brain
November 13, 2018 - Drug therapy can improve outcomes for acutely ill heart patients
November 13, 2018 - Three landmark studies provide better understanding of sudden cardiac arrest
November 13, 2018 - Cholesterol control revised in the latest AHA/ACC guidelines
November 13, 2018 - Vulnerable young teenagers urgently need better sex education, say researchers
November 13, 2018 - Breakthrough research reveals how deadly pneumococcus avoids immune defenses
November 13, 2018 - Researchers discover possible path forward in preventing cancers tied to two viruses
November 13, 2018 - Wishes can help pediatric patients to get better over time
November 13, 2018 - Janssen Reports Positive Topline Results for FLAIR Phase 3 Study of a Novel, Long Acting Injectable Two-Drug Regimen for the treatment of HIV-1
November 13, 2018 - Experimental compound reduces Gulf War illness-like behavior in mice
Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients

Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients

image_pdfDownload PDFimage_print

NEW YORK & INDIANAPOLIS–(BUSINESS WIRE October 23, 2018 )–Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today
announced complete results from a Phase 3 study evaluating the efficacy
and safety of subcutaneous administration of tanezumab, an
investigational humanized monoclonal antibody, in patients with
osteoarthritis (OA) pain treated for 16 weeks. The study met all three
co-primary efficacy endpoints, demonstrating that among patients with
moderate-to-severe OA pain of the knee or hip, both dosing regimens of
tanezumab were associated with a statistically significant improvement
in pain, physical function and patient’s global assessment of their OA,
compared to placebo. These data were presented during a late-breaking
oral session at the 2018 American College of Rheumatology/Association of
Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting in
Chicago.

“The results demonstrated by tanezumab in this study are particularly
meaningful, given that patients had moderate-to-severe pain and were
unable to achieve adequate pain relief with other treatment options,
including opioids and NSAIDs,” said Ken Verburg, tanezumab development
team leader, Pfizer Global Product Development. “Our goal is to be able
to offer tanezumab as a potential non-opioid treatment option for these
patients suffering from osteoarthritis pain.”

More than 27 million Americans are living with OA, a progressive disease
that can cause ongoing debilitating pain. Treatments for OA pain are
limited, and many individuals are unable to find relief from or tolerate
currently available options. Tanezumab is part of an investigational
class of pain medications known as nerve growth factor (NGF) inhibitors,
and in addition to OA pain, is also being studied as a potential
treatment for chronic low back pain (CLBP) and cancer pain (due to bone
metastases). If approved, tanezumab would be a first-in-class,
non-opioid treatment for OA pain and CLBP.

“Pfizer and Lilly each have a long-standing heritage of scientific
innovation in developing novel pain treatments and a shared commitment
to the development of tanezumab,” said Christi Shaw, senior vice
president, Eli Lilly and Company and president, Lilly Bio-Medicines.
“These initial results from our Phase 3 program for tanezumab are
promising, and we’re eager to gain further insights as additional data
report out next year.”

The Phase 3 OA study evaluated changes from baseline to 16 weeks for
three co-primary efficacy endpoints of pain intensity and physical
function, assessed using the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) subscale and patient’s overall assessment
of their OA (PGA-OA). At 16 weeks of treatment, tanezumab was associated
with a significant reduction in pain compared to placebo; additional
efficacy findings are detailed in the table below.

Placebo

Tanezumab

2.5 mg

Tanezumab

2.5/5 mg

N = 232 N = 231 N = 233
WOMAC Pain: Change from Baseline (p-value) versus placebo -2.6 -3.2* -3.4**
Reduction from Baseline at Week 16
≥30% 54.7% 68.0%** 70.4%***
≥50% 37.9% 54.5%*** 57.1%***
≥70% 25.0% 34.6%* 36.5%**
≥90% 9.5% 14.7% 14.2%
WOMAC Physical Function: Change from Baseline (p-value)
versus placebo
-2.6 -3.2** -3.5***
PGA-OA: Change from Baseline (p-value) versus placebo -0.65 -0.87* -0.90**

*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 vs. placebo

In the study, nasopharyngitis (common cold), pain in extremity and
paresthesia (tingling or numbing) were the most common adverse events
(AEs ≥3%) and had a higher frequency in both tanezumab treatment groups
compared to placebo-treated patients. Tanezumab was generally well
tolerated, with 0.4 percent and 1.3 percent of patients in the tanezumab
2.5 mg and 2.5/5 mg arms, respectively, discontinuing treatment due to
AEs; 1.3 percent of patients in the placebo arm discontinued treatment
due to AEs.

There were no cases of osteonecrosis observed in the study. Rapidly
progressive osteoarthritis (RPOA) was observed with tanezumab-treated
patients at a frequency of 1.3 percent and was not observed in the
placebo arm. The incidence of RPOA type 1 (accelerated joint space
narrowing) in the tanezumab 2.5 mg and 2.5/5 mg arms was 1.3 and 0.4
percent, respectively, and the incidence of RPOA type 2 (damage or
deterioration of the joint) was 0.9 and 0 percent, respectively. In the
study, 3.5 percent and 6.9 percent of patients receiving tanezumab 2.5
mg and 2.5/5 mg, respectively, had total joint replacement surgery,
compared to 1.7 percent receiving placebo. The majority of surgeries (68
percent) took place after treatment was completed, during or shortly
after the 24-week safety follow-up period of the study. All surgeries in
this study took place among patients with more severe OA at screening
(Kellgren-Lawrence grade 3-4).

The Phase 3 global clinical development program evaluating the efficacy
and safety of tanezumab includes six studies in approximately 7,000
patients with OA pain, CLBP and cancer pain (due to bone metastases).
Additional readouts from the Phase 3 program are anticipated beginning
in the first half of 2019.

About the Study

The Phase 3 OA study (A4091056) was a 16-week randomized, double-blind,
placebo-controlled, multicenter, parallel-group trial evaluating the
efficacy and safety of subcutaneous administration of tanezumab compared
to placebo in patients with OA of the knee or hip. The trial included a
24-week safety follow-up period. In the study, patients were enrolled
with moderate-to-severe OA pain who had experienced inadequate pain
relief with other treatment options for OA pain or were unable to take
other pain medications. A total of 698 patients were randomized to three
treatment groups in a 1:1:1 ratio to receive two injections over the
16-week treatment period, once every eight weeks; 696 patients received
treatment. One group received two doses of placebo, the second group
received two doses of tanezumab 2.5 mg, and the third group received one
dose of tanezumab 2.5 mg followed by one dose of tanezumab 5 mg eight
weeks later.

Efficacy in the study was measured based on change from baseline to 16
weeks using the WOMAC Pain and Physical Function subscales (11-point
numerical rating scale, where higher scores indicate higher pain levels
or worse function) and PGA-OA scores (5-point numerical rating of the
patient’s condition, where 1 equals “very good” and 5 equals “very
poor”). The average baseline scores for this moderate-to-severe patient
population were as follows: the WOMAC Pain and Physical Function
subscales were approximately 7.1 to 7.4, and the PGA-OA scores were
approximately 3.4 to 3.5 across the treatment groups.

About Tanezumab

Tanezumab is an investigational humanized monoclonal antibody that works
by selectively targeting, binding to and inhibiting NGF. NGF levels
increase in the body as a result of injury, inflammation or in chronic
pain states. By inhibiting NGF, tanezumab may help to keep pain signals
produced by muscles, skin and organs from reaching the spinal cord and
brain. Tanezumab has a novel mechanism that acts in a different manner
than opioids and other analgesics, including nonsteroidal
anti-inflammatory drugs (NSAIDs), and in studies to date, tanezumab has
not demonstrated a risk of addiction, misuse or dependence.

In 2013, Pfizer and Lilly entered into a worldwide co-development and
co-commercialization agreement for the advancement of tanezumab. In June
2017, Pfizer and Lilly announced that the U.S. Food and Drug
Administration (FDA) granted Fast Track designation for tanezumab for
the treatment of OA pain and CLBP. Tanezumab is the first NGF inhibitor
to receive Fast Track designation, a process designed to facilitate the
development and expedite the review of new therapies that treat serious
conditions and fill unmet medical needs.

About Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com and
follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and
like us on Facebook at Facebook.com/Pfizer.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to
make life better for people around the world. We were founded more than
a century ago by a man committed to creating high-quality medicines that
meet real needs, and today we remain true to that mission in all our
work. Across the globe, Lilly employees work to discover and bring
life-changing medicines to those who need them, improve the
understanding and management of disease, and give back to communities
through philanthropy and volunteerism. To learn more about Lilly, please
visit us at www.lilly.com and http://newsroom.lilly.com/socialchannels.

PFIZER DISCLOSURE NOTICE: The information contained in this release
is as of October 23, 2018. Pfizer assumes no obligation to update
forward-looking statements contained in this release as the result of
new information or future events or developments.

This release contains forward-looking information about a product
candidate, tanezumab, including its potential benefits, that involves
substantial risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, the uncertainties
inherent in research and development, including the ability to meet
anticipated clinical trial commencement and completion dates and
regulatory submission dates, as well as the possibility of unfavorable
clinical trial results, including unfavorable new clinical data and
additional analyses of existing clinical data; the risk that clinical
trial data are subject to differing interpretations, and, even when we
view data as sufficient to support the safety and/or effectiveness of a
product candidate, regulatory authorities may not share our views and
may require additional data or may deny approval altogether; whether
regulatory authorities will be satisfied with the design of and results
from our clinical studies; whether and when new drug applications may be
filed in any jurisdictions for tanezumab; whether and when any such
applications may be approved by regulatory authorities, which will
depend on the assessment by such regulatory authorities of the
benefit-risk profile suggested by the totality of the efficacy and
safety information submitted and, if approved, whether tanezumab will be
commercially successful; decisions by regulatory authorities regarding
labeling and other matters that could affect the availability or
commercial potential of tanezumab; and competitive developments.

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2017 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results”, as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

LILLY DISCLOSURE NOTICE: This press release contains forward-looking
statements (as that term is defined in the Private Securities Litigation
Reform Act of 1995) about tanezumab as a potential treatment for
patients with osteoarthritis, chronic low back pain, and cancer pain,
and reflects Lilly’s current beliefs. However, as with any
pharmaceutical product, there are substantial risks and uncertainties in
the process of drug development and commercialization. Among other
things, there is no guarantee that future study results will be
consistent with study findings to date, or that tanezumab will be
approved by the U.S. FDA or other regulatory authorities on the
anticipated timeline or at all, or that tanezumab will be commercially
successful. For further discussion of these and other risks and
uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings
with the United States Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements to reflect events after the date of this release.

Source: Pfizer Inc.

Posted: October 2018

Tagged with:

About author

Related Articles